statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) Director Richard S. Levy sold 11,000 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells $2,832,280.00 in Stock

Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares

Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares

Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares

Investors eyeing a purchase of Madrigal Pharmaceuticals Inc (MDGL) stock, but tentative about paying the going market price of 246.01/share, might benefit from considering selling puts among the...

Commit To Buy Madrigal Pharmaceuticals At $170, Earn 11.6% Annualized Using Options

CONSHOHOCKEN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

For Immediate ReleaseChicago, IL &ndash; April 1, 2024 &ndash; Today, Zacks Investment Ideas feature highlights SPDR S&P Biotech ETF XBI, iShares Biotech ETF IBB, Viking Therapeutics VKTX and...

Zacks Investment Ideas feature highlights: SPDR S&P Biotech ETF, iShares Biotech ETF, Viking Therapeutics and Madrigal Pharmaceuticals

StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL - Free Report) to a sell rating in a research note published on Thursday morning. A number of other research firms have also...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Raised to "Sell" at StockNews.com

Relatively small biotechs can see their shares soar -- sometimes significantly -- following positive clinical or regulatory news.That's what has happened this year to Viking Therapeutics (NASDAQ...

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. &ldquo;Hawkish&rdquo; Federal Reserve Policy, a brutal bear...

2 Top Biotech Buyout Candidates

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Volume	441,775.00
52-Wk High	$313.11
52-Wk Low	$119.76

Period	Estimated	Reported	Surprise	Result
Q1'24	-$6.22	--	--	N/A
Q4'23	-$5.26	-$5.68	-7.92%	MISSED
Q3'23	-$4.90	-$5.34	-9.08%	MISSED
Q2'23	-$4.59	-$4.69	-2.13%	MISSED
Q1'23	-$4.96	-$4.23	14.67%	BEAT

MDGL Madrigal Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals